Neuland commissions first commercial peptide module, adding 7,000L capacity

The wire

1. 01Neuland Laboratories has operationalised its first commercial peptide manufacturing module with 7,000L of reactor capacity, moving peptide API work from development scale to commercial scale.
2. 02Peptide API capacity outside China and Europe matters to sponsors and compounders watching supply diversification for complex peptide drug substances.
3. 03Analyst and investor meetings run 23 to 25 September, where capacity utilisation and customer pipeline may be discussed; the company reported Q1 FY27 net sales of ₹641.58 crore versus ₹292.75 crore a year earlier.

From the source

Neuland Laboratories (NSE: NEULANDLAB) Investor Meeting and Peptide Capacity Expansion Update

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn More